Sipuleucel-T

Sipuleucel-T
Clinical data
Trade namesProvenge
Other namesAPC8015
AHFS/Drugs.comMicromedex Detailed Consumer Information
MedlinePlusa611025
License data
Pregnancy
category
  • N/A (only approved in men, prostate cancer)
Routes of
administration		Intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
  • None
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
 NY (what is this?)  (verify)

Sipuleucel-T, sold under the brand name Provenge, developed by Dendreon Pharmaceuticals, LLC, is a cell-based cancer immunotherapy for prostate cancer (CaP).[1][3][4] It is an autologous cellular immunotherapy.[1]

  1. ^ a b c "Provenge- sipuleucel-t injection". DailyMed. Retrieved 22 July 2021.
  2. ^ Cite error: The named reference FDA Provenge was invoked but never defined (see the help page).
  3. ^ Cite error: The named reference Plosker_2011 was invoked but never defined (see the help page).
  4. ^ Cite error: The named reference US6210662 was invoked but never defined (see the help page).
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.